In Vivo Fluorescent Labeling of Tumor Cells with the HaloTag® Technology

Citation

Published Version
doi:10.2174/1875397301206010048

Permanent link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:10579114

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

Share Your Story
The Harvard community has made this article openly available. Please share how this access benefits you. Submit a story.

Accessibility
In Vivo Fluorescent Labeling of Tumor Cells with the HaloTag® Technology

Jen-Chieh Tseng*1, Hélène A. Benink3, Mark G. McDougall4, Isabel Chico-Calero2 and Andrew L. Kung1,2

1Lurie Family Imaging Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
2Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
3Research and Development Department, Promega Corporation, Madison, WI, USA
4Research and Development Department, Promega Biosciences, LLC, San Luis Obispo, CA, USA

Abstract: Many fluorescent sensors are currently available for in vitro bio-physiological microscopic imaging. The ability to label cells in living animals with these fluorescent sensors would help translate some of these assays into in vivo applications. To achieve this goal, the first step is to establish a method for selectively labeling target cells with exogenous fluorophores. Here we tested whether the HaloTag® protein tagging system provides specific labeling of xenograft tumors in living animals. After systemic delivery of fluorophore-conjugated ligands, we performed whole animal planar fluorescent imaging to determine uptake in tag-expressing HCT116 xenografts. Our results demonstrate that HaloTag ligands containing red or near-infrared fluorophores have enhanced tumor uptake and are suitable for non-invasive in vivo imaging. Our proof-of-concept results establish feasibility for using HaloTag technology for bio-physiological imaging in living animals.

Keywords: Fluorescent imaging, HaloTag, tumor xenograft, in vivo labeling.

INTRODUCTION

The major goal of molecular imaging is to non-invasively monitor bio-physiological activities in living organisms. Recent advancements in fluorescent probe development have made it possible to monitor bio-physiological changes, such as pH [1], ions [2], redox state [3], and membrane potential [4] within living cells using microscopy. Extending the use of such bio-physiological sensors into animal models would be of great interest for biomedical research and drug development.

A common method used to enable fluorescence imaging of cells is via ectopic expression of recombinant fluorescent proteins, such as green-fluorescent protein (GFP), red-fluorescent protein (RFP) and their variants [5]. Specific expression of fluorescent proteins can be achieved via tissue-specific promoters or gene delivery vector systems, and their expression can be readily monitored both by microscopy and with non-invasive imaging in live animals. However, it is difficult to develop physiological sensors based on fluorescent proteins [6]. The deeply buried fluorescent core within the protein makes it challenging to couple fluorescence with sensors of external changes without adversely affecting the fluorescence efficiency of the protein. Another common strategy for in vivo fluorescence imaging is to use fluorophore-conjugated antibodies for cell labeling [7]. However, relatively weak binding affinities and rapid probe clearance make antibody-fluorophore conjugates unsuitable for stable and long-term staining. In addition, antibody-based probes are intrinsically larger than small, membrane-permeable fluorophores, and thus cannot be used to monitor intracellular processes.

The HaloTag technology provides a promising alternative for in vivo fluorescent labeling. Developed based on a modified bacterial haloalkane dehalogenase, the protein tag is capable of covalent linkage to its synthetic ligands [8]. This labeling is irreversible and based upon specific interaction with the tag protein. More importantly, because the ligand is comprised of a small chloroalkane linker (responsible for interaction with the tag) and a functional moiety, novel ligands are easily made by attaching this linker to a variety of physiological sensors [9]. Further, compared with conventional fluorescent proteins and antibody-conjugates, these synthetic fluorescent ligands are smaller and can be membrane permeable. Of particular interest to the present study, monitoring of intracellular pH changes has been previously reported using a HaloTag ligand that contains a pH sensing module SNARF-1™ [10]. To further investigate the possibility of translating the HaloTag technology from in vitro cell-based to in vivo animal applications, we performed fluores-
cent labeling of tag-expressing cancer cells in living animals which are known to be exposed to an acidic pH environment during tumorogenesis. Using a HaloTag-expressing HCT116 human colon cancer xenograft model and either a NIR standard fluorescent ligand or the pH sensing SNARF-1™ ligand, we provide proof-of-principle for tag-specific labeling after systemic delivery of fluorescent ligands.

MATERIALS AND METHODS

Fluorescence Spectrum Unmixing of SNARF HaloTag Ligand at Different pH

The SNARF HaloTag ligand is the parent structure of the previously described AcSNARF(06)Cl [10]. In brief, SNARF-1™ (in the form of carboxylic acid, acetate, succinimidyl ester, Invitrogen, Carlsbad, CA) was reacted with the HaloTag chloroalkane amine linker, NH₂(CH₂CH₂O)₆(CH₂)₆Cl, to form SNARF-(O6)-Cl, which is referred to as SNARF ligand throughout the manuscript. To determine the fluorescence properties of this ligand at various pH, we performed fluorescence imaging in a black 96-well plate using 50 µg of the ligand in 300 µL of PBS, with pH ranging from pH 5.4 to pH 10.8.

Using the IVIS Spectrum system (Caliper Life Sciences, Hopkinton MA), the plate was sequentially imaged with a fixed excitation filter at 535 nm to determine the optimal emission in the range from 580 nm to 840 nm (1 sec, F-stop = 2, small binning). The acidic and basic SNARF fluorescence spectra were reconstructed using spectral unmixing (Living Image Software Version 4.2, Caliper Life Sciences, Hopkinton MA).

Cellular Labeling Using SNARF HaloTag Ligand in Vitro

A pCINeo-HT7 plasmid containing a cytosolic HaloTag protein expression cassette was stably transfected into HCT116 human colon cancer cells. The HaloTag-expressing cells (HCT116-HT) were cultured in DMEM with 10% FBS under selection with G418 (1 µg/mL). For in vitro cell labeling, HCT116-HT and parental HCT116 cells were incubated in culture media containing 20 µM of SNARF-1 ligand at 37°C for 15 min. After three washes with PBS, cells were incubated with fresh media for 30 min prior to imaging on a Nikon Eclipse Ti inverted fluorescence microscope.

In Vivo Spectral Characterization of SNARF HaloTag Ligand

In order to reconstruct the acidic and basic SNARF fluorescence spectra in vivo, NCr nude mice were subcutaneously inoculated with 3 x 10⁶ HCT116 (left flank) or HCT116-HT (right flank) cells. Animals were fed an alfalfa-free diet to reduce background autofluorescence. After two weeks, each tumor-bearing mouse received a single intravenous injection of SNARF ligand (1 mg dissolved in 100 µL of 20% DMSO and 80% PBS). The day after injection, sequential fluorescent images were acquired using the IVIS Spectrum system. With a fixed Ex 535 nm filter, we performed emission scanning ranging from 580 to 800 nm (1 sec, small binning and F-stop = 2). Using the Living Image software package, the tissue autofluorescence and the SNARF fluorescence were unmixxed and spectra for both components were reconstructed. We determined the optimal excitation wavelength by scanning from 535 to 640 nm, with a fixed 700 nm emission filter (1 sec, F-stop = 2 and small binning).

In Vivo Uptake of Fluorescent Ligands in HaloTag-expressing Tumor Xenografts

NCr nude mice with tumor xenografts (left: HCT116; right: HCT116-HT) received intravenous injections of 1 mg SNARF ligand (in 100 µL of 20% DMSO and 80% PBS). The ligand distribution was subsequently determined by fluorescence imaging 1 h (day 0), 1 day and 2 days after probe injection with an Ex 640/Em 700 filter pair (1 sec, F-stop = 2 and small binning). Statistical analysis was performed using Prism (Version 5.02, GraphPad, La Jolla, CA).

To generate the IRDye800 HaloTag ligand, HaloTag chloroalkane amine linker, NH₂(CH₂CH₂O)₆(CH₂)₆Cl, was reacted with the IRDye800CW™ NHS ester (LI-COR, Lincoln NE) to form IRDye800-O4-Cl, which is referred to as IRDye800 ligand throughout the study. For in vivo tumor labeling with the IRDye800 ligand, NCr nude mice with tumor xenografts on the flanks (left: HCT116; right: HCT116-HT) received intravenous injections of 0.25 mg IRDye800 ligand (in 200 µL of 10% DMSO and 90% PBS). Ligand distribution was determined 2 h (day 0), 1 day, 2 days and 3 days after probe injection, using an Ex 745 nm/Em 800 filter set (1 sec, F-stop = 2 and small binning). Statistical analysis was performed using Prism.

All animal studies were performed under protocols approved by the DFCI ACUC.

RESULTS

The SNARF-1™ conjugated ligand was first validated in vitro as a pH sensor. SNARF ligand was dissolved in PBS at various pH (from acidic pH 5.4 to basic pH 10.8) in a black opaque 96-well plate (Fig. 1). With a fixed excitation wavelength at 535 nm, we scanned the plate for optimal emission settings (from 580 nm to 840 nm) in an attempt to distinguish the acidic and the basic forms of SNARF ligand (Fig. 1A). Using spectral unmixing, we reconstructed two fluorescence emission components corresponding to the acidic and basic spectra of the SNARF ligand (Fig. 1B). The reconstructed spectra indicate that the maximal emission is ~580 nm for acidic SNARF, and ~640 nm for basic dye (Fig. 1C).

To assess HaloTag function in vivo, we generated HaloTag-expressing xenograft tumors. Human HCT116 colon cancer cells were stably transfected with a cytosolic HaloTag expression plasmid to form the stable cell line HCT116-HT. After labeling with SNARF ligand in vitro, fluorescence was observed in the HCT116-HT cells, but not parental HCT116 cells (Fig. 2).

We next tested if the SNARF ligand can label HCT116-HT tumors in vivo after systemic administration. Athymic nude mice were simultaneously inoculated with HCT116 (left) and HCT116-HT (right) cells. After establishment of subcutaneous tumors, mice were intravenously injected with SNARF ligand. Using a 535 nm excitation filter, we performed sequential emission scanning 24 h after probe injection covering the emission range from 580 to 800 nm,
Fig. (1). Fluorescence spectral unmixing of SNARF ligand at different pH.

(A) SNARF ligand fluorescence was assessed across the indicated pH range by sequential imaging using a fixed excitation filter at 535 nm. Fluorescence emission was acquired from 580 nm to 840 nm. (B) The acidic and basic SNARF fluorescent components were reconstructed after spectral unmixing. A composite image was generated with green and red pseudocolors representing the acidic and basic fluorescence respectively. (C) The unmixed spectra of the acidic (green) and basic (red) fluorescence of SNARF in vitro.

Fig. (2). SNARF ligand preferentially labels HaloTag-expressing HCT116 cells.

The HaloTag expression cells (HCT116-HT) and non-tag expressing parental cells (HCT116) were labeled with SNARF ligand prior to fluorescence microscopic imaging. Labeling by the SNARF ligand was observed homogenously in the HaloTag-expressing cells (merge). No red fluorescence was observed in the parental HCT116 cells. A corresponding bright-field image was acquired reveal morphology of cells. The width of the view is 150 μm.

(Fig. 3A). Unfortunately, there was significant interference from tissue autofluorescence at this excitation wavelength, resulting in low S/N ratios in tumors (Fig. 3B). Although spectral unmixing of the sequential imaging data was capable of distinguishing SNARF fluorescence from tissue autofluorescence (Fig. 3C), the reconstructed SNARF spectrum revealed considerable overlap with autofluorescence (Fig. 3D). Thus, the optimal settings for in vitro imaging (Ex 535 /Em 580 for acidic and Ex 535 /Em 640) were confounded by significant autofluorescence in vivo.
To decrease autofluorescence and enhance SNARF signal detection in vivo, we investigated higher excitation wavelengths coupled with a 700 nm emission filter. Scanning excitation wavelengths spanning 535-640 nm revealed that a 640 nm excitation resulted in intense SNARF fluorescence and better S/N ratios in tumors (Fig. 3E, F). In addition to decreased autoflourescence, the more red-shifted excitation and emission wavelengths enable better tissue penetration.

Using this optimized in vivo setting (Ex 640 nm/ Em 700 nm), we were able to determine the kinetics of SNARF ligand uptake and retention in tumors (Fig. 4). After systemic probe injection, higher SNARF uptake was observed in the HaloTag-expressing tumor throughout the course of imaging (Fig. 4A) and HaloTag-associated signals lasted for at least 2 days after injection (Fig. 4B). Using the fluorescent signal in the neck region as reference, HCT116-HT tumors exhibit above background fluorescence (Fig. 4B). Although it was determined that tag-expressing tumors had statistically significant signal-to-noise over background (p<0.05), we did observe background SNARF signal in parental HCT116 tumors. In addition to uptake in tumors, above-background signal was observed in the gastrointestinal tract 1 day after probe injection (Fig. 4C).

To further enhance sensitivity, we further explored the possibility of using a near-infrared ligand to improve tissue penetration. A HaloTag ligand was conjugated with IRdye

Fig. (3). In vivo spectral property of SNARF HaloTag ligand.
NCr nude mice were subcutaneously inoculated with HCT116 control (left, yellow arrow) and HCT116–HT (right, blue arrow) cells. Mice with established tumors received intravenous injection of SNARF-1 ligand. Sequential planar fluorescence images were acquired 1 day after probe injection with a fixed excitation wavelength at 535 nm. (A) Fluorescence was imaged with emission filters spanning 580-800 nm. (B) S/N ratios were calculated using the neck as background. (C) Two fluorescence components were reconstructed by spectral unmixing, one representing the tissue autofluorescence (AF) and the other representing the SNARF fluorescence. A composite image was generated using green and red pseudocolors for tissue AF and SNARF signals respectively. (D) The unmixed spectra for the tissue AF (green) and SNARF signals (red) shows considerable overlap. (E) Optimal SNARF excitation was determined spanning 535-640 nm with a fixed emission at 700 nm. (F) Optimum excitation at 640 nm provides deeper penetration and stronger SNARF fluorescence with highest S/N ratios.
In this study, we provide proof-of-principle for using HaloTag-mediated fluorescence labeling of tumor cells in living animals. We demonstrate that fluorophore-conjugated ligands are well tolerated after systemic delivery and there is selective fluorescence uptake in HaloTag-expressing tumors in vivo. Although the uptake was enhanced in HaloTag-expressing tumors, we did observe some non-selective signal in tag-negative tumors, likely due to EPR effects (enhanced permeability and retention), which is commonly found in rapidly growing tumors. Many fluorophores demonstrate considerable EPR effects after systemic delivery, resulting in non-specific trapping within tumor stroma [11, 12]. Further, we also observed some non-specific fluorescent signal in the abdominal region. We believe that this is likely due to the ligands’ hydrophobicity/hydrophilicity, as well as other parameters (e.g. pKa, electric charge, aromatic size, and amphiphilic index) which are known to influence pharmacokinetics and clearance in animal models. Further, it is also possible that the conjugated ligand may interact with tissue components in a non-selective manner in the animal. As all ligands for HaloTag contain a chloroalkane in addition to the functional moiety, we plan to modify this region in future studies.

DISCUSSION

In this study, we provide proof-of-principle for using HaloTag-mediated fluorescence labeling of tumor cells in living animals. We demonstrate that fluorophore-conjugated ligands are well tolerated after systemic delivery and there is selective fluorescence uptake in HaloTag-expressing tumors in vivo. Although the uptake was enhanced in HaloTag-expressing tumors, we did observe some non-selective signal in tag-negative tumors, likely due to EPR effects (enhanced permeability and retention), which is commonly found in rapidly growing tumors. Many fluorophores demonstrate considerable EPR effects after systemic delivery, resulting in non-specific trapping within tumor stroma [11, 12]. Further, we also observed some non-specific fluorescent signal in the abdominal region. We believe that this is likely due to the ligands’ hydrophobicity/hydrophilicity, as well as other parameters (e.g. pKa, electric charge, aromatic size, and amphiphilic index) which are known to influence pharmacokinetics and clearance in animal models. Further, it is also possible that the conjugated ligand may interact with tissue components in a non-selective manner in the animal. As all ligands for HaloTag contain a chloroalkane in addition to the functional moiety, we plan to modify this region in future studies.
In Vivo Fluorescent Labeling of Tumor Cells

Current Chemical Genomics, 2012, Volume 6

Fig. (5). *In vivo* uptake of IRdye800 ligand in HaloTag-expressing tumor xenografts. For *in vivo* tumor labeling with the IRdye800 ligand, NCr nude mice bearing control HCT116 (left, yellow arrow) and HCT116–HT tumors (right, blue arrow) on the flanks were intravenously injected with 0.25 mg of the IRdye800 ligand. (A) Planar fluorescence imaging was performed 1 h (day 0) and 1, 2 and 3 days after probe injection with Ex 745 nm/ Em 800 nm filters. (B) Enhanced IRdye800 fluorescence was observed in the HT-expressing tumors. (C) Quantitative analysis shows significant increase of IRdye800 fluorescence in HT-positive tumors. The left panel illustrates the fluorescence efficiency of tumors. The right panel indicates the relative S/N ratios of tumors, normalized to fluorescence at the neck as reference. (D) IRdye800 ligand uptake was observed in the gastrointestinal track as early as 2 h after injection.

Labeling of cells or tissues with exogenously delivered fluorophores is the first step toward successful *in vivo* physiological fluorescence imaging. Several hurdles need to be overcome in order to make this technology more practical for *in vivo* use. In general, compared with bioluminescence methods, fluorescence imaging methods have higher auto-fluorescence and thus lower signal-to-noise ratios. Spectral shifts resulting from microenvironmental influences (e.g., pH, protein binding, and pigments) also impact *in vivo* fluorescence imaging. In addition to the ligand linker modifications mention above, another way to circumvent such issues is to develop fluorescent probes that are fluorescently inert but can be effectively activated by specific intracellular biological activities. Such “gain-of-function” fluorescence sensors may significantly reduce non-specific noise, allowing for improved sensitivity and specificity for *in vivo* imaging.

In the current study, we tested the uptake of fluorescent ligands by a HaloTag protein which is small enough to reside throughout the interior of cell. However, fusion of HaloTag to proteins with precise subcellular localizations could be used to monitor biophysiological changes in particular subcellular structures of interest, such as the nucleus, mitochondria or plasma membrane. Fusion of the tag with proteins of better stability and longer half-life could prolong fluorescent signal retention with target cells. Another potential application is to use HaloTag fusion proteins, in conjunction with
bioluminescence, for \textit{in vivo} BRET imaging \cite{13}. With the current success and wide adaptation of the HaloTag technology for \textit{in vitro} applications, our results suggest that the technology also has potential to become a versatile platform for \textit{in vivo} imaging.

**CONFLICT OF INTEREST**

Some authors on this study are employees of Promega Corporation or Promega Biosciences, LLC.

**ACKNOWLEDGEMENT**

This work was supported by the Nancy Lurie Marks Foundation.

**REFERENCES**


